Literature DB >> 3685060

Differential effects of physostigmine on cues produced by electrical stimulation of the ventral tegmental area using two discrimination procedures.

J P Druhan1, M T Martin-Iverson, D M Wilkie, H C Fibiger, A G Phillips.   

Abstract

Two procedures were employed to assess the effects of physostigmine on the discrimination of cues produced by either high or low intensity electrical brain stimulation (EBS) of the ventral tegmental area in rats. When the procedure involved frequent presentation of brief trials, physostigmine enhanced the perceived intensities of the cues, causing the rats to respond to low intensities as though they had higher values. In contrast, physostigmine had no effects on the discrimination when the trials were less frequent and extended in duration. These results confirm the existence of multiple substrates for cues produced by stimulation of the ventral tegmental area in rats and implicate cholinergic neurons as substrates for the non-dopaminergic cues identified in the companion paper.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3685060     DOI: 10.1016/0091-3057(87)90223-1

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  3 in total

1.  Differential effects of cholinergic drugs on discriminative cues and self-stimulation produced by electrical stimulation of the ventral tegmental area.

Authors:  J P Druhan; H C Fibiger; A G Phillips
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  The effects of reinforcer magnitude on timing in rats.

Authors:  Elliot A Ludvig; Kent Conover; Peter Shizgal
Journal:  J Exp Anal Behav       Date:  2007-03       Impact factor: 2.468

3.  On the Similarity Between the Reinforcing and the Discriminative Properties of Intracranial Self-Stimulation.

Authors:  David N Velazquez-Martinez; Benita Lizeth Pacheco-Gomez; Ana Laura Toscano-Zapien; Maria Almudena Lopez-Guzman; Daniel Velazquez-Lopez
Journal:  Front Behav Neurosci       Date:  2022-02-21       Impact factor: 3.558

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.